Clinical trials: Cone-Rod Dystrophy
Retinal Degeneration, Retinitis Pigmentosa
Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Patients who are legally blind, caused by retinal degeneration of photoreceptor rods \& cones (e.g. Retinitis pigmentosa), receive a subretinal implant to restore vision partially.
- Trial name
- NCT01497379
- Testing
- surgical implantation of subretinal device
- Where
- Hong Kong
- Volunteers
- 2 people
- Sponsor
- Retina Implant AG
Retinal Degeneration, Inherited Retinal Dystrophy Primarily Involving Sensory Retina
Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS
This study aims to assess the impact of the subretinal implant RETINA IMPLANT Alpha AMS on the patient's daily life, using validated activities of daily living and questionnaires.
- Trial name
- NCT03561922
- Testing
- RETINA IMPLANT Alpha AMS
- Where
- 2 sites in France
- Volunteers
- 2 people
- Sponsor
- Retina Implant AG
Cone-Rod Degeneration, Rod-Cone Degeneration
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Background: The retina is a thin layer of tissue at the back of the eye. Retinal disease usually reduces a person s mobility because it affects how he or she moves through familiar and unfamiliar environments.
- Trial name
- NCT04289571
- Testing
- VR Mobility Tool
- Where
- 2 sites in United States, Australia
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Neurogenic Detrusor Overactivity
Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity
This is a prospective, multicentre (7 sites), randomized, double-blind, study comparing intravesical injection of BOTOX to placebo in 56 subjects with NDO secondary to spinal cord injury or multiple sclerosis.
- Trial name
- NCT01091727
- Testing
- Botulinum toxin A
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- Sunnybrook Health Sciences Centre
Retinitis Pigmentosa
A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)
The primary objective of the study is to assess the safety and tolerability of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution administered over 6 months versus a vehicle control in patients…
- Trial name
- Lumos (NCT02110225)
- Testing
- rhNGF 60 µg/ml eye drops solution, rhNGF 180 µg/ml eye drops solution
- Where
- 5 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Dompé Farmaceutici S.p.A
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy
This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone…
- Trial name
- NYRVANA (NCT07807111)
- Testing
- SPVN20 (high dose), SPVN20 (medium dose), SPVN20 (low dose)
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 27 people
- Sponsor
- SparingVision